Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

(e) Named Executive Officer Compensation



On January 25, 2023, the Board of Directors of Soleno Therapeutics, Inc., (the
"Company") following a review of the Company's executive compensation program by
its Compensation Committee and recommendations, approved certain increases to
the base salaries for fiscal year 2023, the payment of cash bonuses for fiscal
year 2022 and certain equity awards for certain named executive officers as
follows:

                                             Fiscal Year 2023 Annual              Fiscal Year 2022 Cash
Name and Principal Position                    Base Salary ($)(1)                    Bonus Award ($)              Options(2)
Anish Bhatnagar
Chief Executive Officer                     $                 556,800 (3)        $               278,400              115,000
James Mackaness
Chief Financial Officer                     $                 400,000            $               154,000               30,000
Patricia Hirano
Vice President of Regulatory Affairs        $                 340,000            $                97,800               20,000
Kristen Yen
Vice President of Clinical Operations       $                 325,000            $                93,360               20,000

(1) Effective as of January 1, 2023.

(2) One forty-eighth (1/48th) of the shares subject to the Option shall vest on

the first month anniversary of January 1, 2023 (the Vesting Commencement

Date), and one forty-eighth (1/48th) of the total number of shares subject to

the Option shall vest each month thereafter on the same day of the month as

the Vesting Commencement Date.

(3) No change from Fiscal Year 2022 Annual Base Salary.





                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses